- Home
- / Therapix Biosciences
Therapix Biosciences
Stock Price
$4.4
2021-01-28
Market Capitalization
$4.5 M
2021-01-28
Revenue
$856 K
FY, 2025
Therapix Biosciences Summary
Company Summary
- Overview
- Therapix Biosciences (formerly NasVax) is a specialty clinical-stage company that focuses on cannabinoid pharmaceuticals. It develops a range of drug candidates for the treatment of Tourette syndrome (TS), obstructive sleep apnea (OSA), pain, mild cognitive impairment (MCI), infectious diseases, and more.
- Type
- Public
- Status
- Active
- Founded
- 2004
- HQ
- Giv'atayim, IL | view all locations
- Website
- https://therapixbio.com/
- Cybersecurity rating
Table of Contents
LocationsView all
1 location detected
Giv'atayim, Tel Aviv District HQ
Israel
Ariel Sharon St 4
Therapix Biosciences Financials
Summary Financials
- Revenue (FY, 2025)
- $856.0K
- Gross profit (FY, 2025)
- $631.0K
- Net income (FY, 2025)
- ($12.6M)
- Cash (FY, 2025)
- $4.6M
- EBIT (FY, 2025)
- ($6.6M)
- Enterprise value
- $230.9K
Footer menu
Product
- Intelligence Suite
- Supplier Intelligence Platform
- Craft Intelligence Portal
- Craft API
- Craft for Teams
- Supplier Intelligence Platform
- Craft Alerts
- Craft N-Tier Mapping
- Craft Risk Hub
- Chrome extension
Resources
© Craft.co 2026